Global and focal changes of regional cerebral blood flow (rCBF) and metabolism are observed in conditions characterized by progressive cogni tive deterioration, such as dementia of the Alz heimer or Pick type (Risberg and Gustafson, 1988) . Characteristic rCBF changes are also associated with the transient cognitive impairment following electroconvulsive therapy (ECT) (Prohovnik et aI. , 1986) . In Alzheimer's disease, the best studied of these conditions, cerebral metabolism declines in association with a decline in neuropsychological function (Frackowiak et aI. , 1981; Friedland et aI. , 1983) . While the neuropsychological changes have been related pathologically to changes in the cho linergic system, the etiology of the changes in cere bral perfusion and metabolism is less clear, but 635 CBF was significantly reduced 25 min after scopolamine. The pattern of regional change in CBF was not similar to Alzheimer's disease. Rather than a focal parietotemporal deficit as seen in Alzheimer's disease, we observed a pre dominantly frontal reduction in flow of about 20%. These results suggest that the frontal but not the parietotem poral deficits seen in several dementing conditions may be related to cholinergic dysfunction. Key Words: Alz heimer's disease-Cerebral perfusion-Acetylcholine Scopolamine.
could also relate to changes in the cholinergic system (Perry et aI. , 1978; Perry et aI. , 1985; Wil cock et aI. , 1982) .
Pharmacological manipulation has been a useful strategy to demonstrate the importance of the cho linergic system to memory functions in health and disease. In normal young subjects, administration of cholinomimetics or acetylcholinesterase inhib itors can enhance memory, while blockade of the cholinergic system with the specific muscarinic an tagonist, scopolamine, results in a transient state of cognitive impairment (Davis et aI., 1978; Drachman and Leavitt, 1974; Sitaram et aI. , 1978) . Elderly subjects given scopolamine become impaired to the degree observed in Alzheimer's disease patients (Sunderland et aI. , 1986) . The Alzheimer's disease patients themselves, as well as parkinsonian pa tients, are more sensitive than normal patients to the effects of scopolamine (Dubois et aI., 1987; Sunderland et aI. , 1987) . Acetylcholinesterase in hibitors may improve memory functions in Alz heimer's disease, especially if used chronically (Kopleman, 1986; Summers et aI., 1986) . Physostig mine is reported to improve memory functions when given to patients after ECT (Levin et aI. , 1987) . Thus, studies using pharmacologic probes support a role for the cholinergic system in memory function and in the cognitive changes associated with dementia.
However, unlike the established relationship be tween the cholinergic system and memory func tions, the effects of cholinergic manipulations on CBF and metabolism in humans are not known. Studies in the rodent indicate that scopolamine ad ministration does result in decreases in cortical blood flow (Dam and London, 1984; Helen and London, 1984; Weinberger et aI. , 1979) . Since the administration of scopolamine to young subjects produces cognitive changes similar in some re spects to Alzheimer's disease, and the deficits of Alzheimer's disease are associated with focal pa rietotemporal perfusion changes (Prohovnik et al. , 1988) , we hypothesized that cholinergic blockade could produce similar perfusion deficits in young subjects. Therefore, the effects of scopolamine on rCBF in normal humans were studied to compare this cholinergic deficit state to those observed in dementing illnesses and further clarify the possible pathophysiology of these changes.
METHODS

Subjects
Fifteen normal subjects (10 men, 5 women, mean age 28.4 years, range 20-48 years) gave informed consent to participate in this study. All were free of medical and psy chiatric illness and none were taking medication. Sub jects were fasted for 3 h prior to the study, tobacco and coffee were not permitted in the hour preceding the study.
rCBF procedures rCBF was measured using the [133Xel inhalation tech nique with 16 detectors over each cerebral hemisphere (Novo Cerebrograph 32c). The rCBF detectors were po sitioned using the canto-meatal line as a reference.
Each rCBF measurement took 11-16 min; pulse rate and blood pressure were measured at regular intervals, and expired carbon dioxide tension (PeC02) was contin uously monitored. rCBF data were analyzed according to the four compartment model and are reported in terms of the fg parameter, a fully quantitative index of gray matter flow (Prohovnik et aI., 1983) . There is an excellent corre lation between rCBF and metabolism in normal brain, and strong indications that the coupling is preserved in Alzheimer's disease brain (Fox and Raichle, 1976; Frack owiak et aI., 1981; Weinberger et aI., 1987) . Therefore, rCBF can be interpreted to reflect metabolism, provided that changes in PeC02 are compensated for with a correc tion factor, here 2.3 ml/lOOg/min/mmHg (Maximilian et aI., 1980) .
Experimental design
Each subject underwent a baseline rCBF study, fol lowed by memory testing. The Wechsler Adult Intelli gence Scale (WAIS-R), Digit Span Subtest (DS) and the Buschke Selective Reminding Te st (BSRT) were adminis tered, the latter expected to be sensitive to the effects of 1988 scopolamine, the former insensitive (Buschke, 1973; Drachman and Leavitt, 1974) . Scopolamine was then ad ministered in one of two doses, followed immediately by two rCBF studies, reported as times 5 and 25 min post infusion. Memory testing was then repeated, approxi mately 35 min post-infusion, followed by a third and final post-infusion rCBF study at 60 min.
In a pilot study, scopolamine at a dose of 6.1 J.,Lg/kg i. v. was found to induce significant cognitive impairment, whereas higher doses were required to affect rCBF (Honer et aI., 1987) . We therefore used two doses of sco polamine, 6.1 J.,Lg/kg i.v. was given to five subjects, and 7.3 J.,Lg/kg i. v. was given to a second group of 10 subjects. Each subject's baseline rCBF study served as a control for comparison to studies after scopolamine, and the low dose group served as a further control for possible habitu ation effects.
Data analysis
Statistical analysis was performed using repeated mea sures analysis of variance (AN OVA) with dose (low/high) as a between subjects factor and time relative to scopol amine infusion (pre-, 5 min post-, 25 min post-) as a within subjects repeated measure. The Greenhouse Geisser adjusted F is reported. The data from the 60 min study was incomplete due to technical problems and was not used in statistical analyses; however at this time rCBF data were returning to baseline levels. Analysis of global flow changes was performed first. Then, analysis of the effects of scopolamine on regional flow at each de tector was performed. We further grouped the five ante rior detectors together into an arbitrary frontal region and compared the effects of scopolamine on the blood flow to this region of the brain to the effect on the rest of the brain.
RESULTS
Physiological responses to scopolamine are shown in Ta ble 1. There was no main effect of dose for these variables. PeC02 was significantly af fected by time after drug at both doses (F2 , 1 2 = 5. 18, p < 0.0 1) and all rCBF data were corrected to the group mean PC02 of 40. 3 mmHg. Of the other vari ables, only systolic blood pressure showed an inter action effect of dose by time (F2 , 12 = 4.40, P < 0.02).
Results of cognitive testing are shown in Ta ble 2. For digit span, there were no main effects of dose or of time. A significant interaction was observed between dose and time for digit span forwards (F 1 , 1 3 = 5.72, p < 0.03). As expected, on the Buschke Selective Reminding Te st, performance was signifi cantly impaired after scopolamine (FI , 13 = 65.85, P < 0.001) without demonstrable main or interaction effects of dosage.
The time course of the change in global CBF is shown in Fig. 1 , suggesting a maximal effect of high dose scopolamine at 25 min. Global CBF showed a significant effect of time (F2 12 = 6.67, p = 0. 0 1), and a significant interaction between time and dose (F2 12 = 8.54, P < 0.0 1). If the incomplete data from 60 �in are also included (n = 14), this interaction effect remains significant (F3,10 = 4. 11, p < 0.05). As shown in Fig. 1 , only the high dose group showed the reduction in flow, maximal at 25 min post-injection, and perfusion returned to control values at 60 min.
The CBF data were further analyzed for each in dividual detector, using the first three runs. Prelimi nary analysis indicated no difference between the hemispheres, and therefore the mean of left and right flows at each detector location were used. For illustrative purposes, the percent change in abso lute flow between baseline and 25 min at each de tector is shown in Fig. 2. In the low dose group, the changes in flow were negligible. In contrast, in the high dose group, flow decreased at every detector. Significant interactions between dose and time oc curred at most detectors, and the significance of this interaction for each detector is also shown in Fig. 2 . Most notable are the large reductions in flow, with significant interaction effects, in the an terior areas. There was no predominance of flow reduction in the parietotemporal area, as seen in Alzheimer's disease (Prohovnik et at., 1988) .
We arbitrarily grouped the data from the five frontal detectors for comparison to the rest of the a Significant effect of time, p < 0.001. b Significant interaction of dose by time, p < 0.0 1 brain. The results of this analysis are shown in Ta ble 3. There was no main effect of dose. Time (F2, 1 2 = 9.83, P < 0.01) and region (F1,13 = 91. 74, P < 0.00 1) were significant, reflecting the overall flow reduction following scopolamine and the well known hyperfrontality. The dose by time interac tion was significant (F2 1 2 = 10.49, P < 0.0 1), due to the greater flow reduction after high dose. The time by region interaction was also significant (F2,12 = 9.89, p < 0.001), reflecting the greater frontal re duction after both doses of scopolamine.
DISCUSSION
This study is the first report of the effects of sco polamine on rCBF in humans. We simultaneously assessed the cognitive effects of the drug, adminis tered at two doses. The cognitive impairments were as expected, at both doses there were impairments in secondary or long-term memory, while primary or short-term memory was unimpaired (Drachman and Leavitt, 1974) . The threshold for these cogni tive effects was lower than that for the CBF effects: whereas global and focal perfusion reductions were seen only with the higher dose, memory deficits were observed following both doses. The cerebral vasculature is supplied by cholin ergic fibers and contains muscarinic receptors (Burnstock, 1980) . The direct effect of acetylcho line (ACh) in this system is vasodilation, and sco polamine could act as a vasoconstrictor (Pearce et aI., 198 1; Estrada et aI. , 1983; Hudson et aI. , 1983) . The decrease in CBF we observed after scopol amine could therefore be due to a vascular effect of the drug, but we consider a purely vascular mecha nism of action unlikely. The delayed time course of the scopolamine effect as well as the regionally het erogeneous decreases in flow more likely reflect changes in parenchymal metabolism.
The effect of ACh on cortical neurons is to in crease their activity, presumably with an associated increase in CBF (Krnjevic and Phillis, 1963; McLennan and Hicks, 1978) . Scopolamine would therefore be expected to decrease local neuronal activity and metabolic demand and consequently reduce CBF. In animal studies using the [ 1 4C]-de oxyglucose method as a measure of cerebral metab olism, scopolamine administration does result in a decrease in cortical metabolism (Dam and London, 1984; Helen and London, 1984; Weinberger et aI., 1979) . These studies are in accord with reports of the effects of stimulation or lesions of the nucleus basalis of Meynert (nbM), the primary origin of cholinergic projections to the cerebral cortex. In rats, stimulation of the nbM increases cortical blood flow (Lacombe et aI. , 1987) . Lesioning the nbM in rats and in primates results in decreases of the presynaptic cholinergic marker choline acetyl transferase (ChAT), along with associated de creases in cerebral metabolism (Kiyosawa et aI. , 1987; Orzi et aI., 1987; Ta naka et aI., 1987) .
The individual detector analysis indicated max imal effects of scopolamine in the anterior regions of the cortex. The mechanism of the anterior pre dominance in the reduction in blood flow we ob served after scopolamine is unclear. This finding is unlikely to be explained on the basis of a more dense cholinergic projection or more dense re ceptor distribution in the area; ChAT and ACh re ceptor binding studies in normal human brains do not show localized increases in either variable fron tally (Davies, 1979; Davies and Maloney, 1976; Perry et aI., 1977; Rossor et aI. , 1982; . One study of Rhesus monkeys did show a relatively in creased cholinergic projection to the paralimbic portions of the frontal and temporal lobes (Me sulam et aI. , 1986). However, these areas are not well visualized by our recording technique and are likely to be responsible for only a minor portion of our observation. Of interest are some reports that the occipital lobes in humans and other primates tend to have the least dense cholinergic projection, thus may be the least sensitive to the effects of sco polamine and have the smallest reduction in flow, as we observed (Lehmann et aI. , 1984; Rossor et aI. , 1982; Yamamura et aI. , 1974) . Despite the absence of a definitive neurochemical correlate for the focal frontal effects of scopolamine, our results are consistent with animal studies which suggested that stimulation or lesions of the nbM have predom inantly frontal effects on CBF and metabolism (Kiyosawa et aI., 1987; Orzi et aI., 1987; Ta naka et aI. , 1987) . Global CBF is reduced in the elderly, and further in Alzheimer's disease patients (Frackowiak et aI. , 198 1; Friedland et aI. , 1983; Mathew et aI. , 1986) . Most characteristic of Alzheimer's disease, how ever, are focal parietotemporal reductions in CBF and metabolism (Friedland et aI. , 1983 , Prohovnik et aI. , 1988 Risberg and Gustafson, 1988) . Scopol amine in young normal subjects does not mimic this effect, however this does not preclude the possi bility of such a response in the normal elderly. A comparable situation may be the cognitive effects of scopolamine in the young versus the elderly. In young subjects, as we observed, scopolamine disrupts long-term memory, while leaving primary or short-term memory intact (Drachman and Lea vitt, 1974) . However, in elderly subjects scopol amine more completely mimics Alzheimer's dis ease, as primary memory as well as secondary or long-term memory is affected (Sunderland et aI. , 1986) . The effects of scopolamine on blood flow in an elderly sample might therefore more completely mimic the effects of Alzheimer's disease.
The anterior deficits in rCBF seen after scopol amine may provide clues to the pathophysiology of the frontal lobe flow deficits seen in a subgroup of Alzheimer's disease patients, in Pick's, and in Par kinson's diseases, and after bilateral electroconvul sive therapy (Bes et aI., 1983; Cutler et aI., 1985; McGeer et aI., 1986; Prohovnik et aI., 1986; Risberg and Gustafson, 1988) . Cholinergic deficits are pro posed to be important in each of these disorders, based on pathological studies, increased sensitivity to anticholinergics, and, in some cases, partial im provement in cognitive function with acetylcholin esterase inhibitors (Dubois et aI., 1987; Levin et aI., 1987; Sunderland et aI., 1987; White et aI. , 1977) . In degenerative disorders, the pathophysiology of the changes in CBF likely involves two interdependent mechanisms. First, there may be changes in neuro chemical function, modelled in our study with the administration of scopolamine. There are undoubt edly also changes in CBF and metabolism due to the histopathological changes of each illness. These changes are reported to correlate well with the rCBF and metabolic patterns of Alzheimer's dis ease and Pick's disease at advanced stages (Fried land et aI. , 1985; Kamo et aI., 1987; McGeer et aI., 1986) . In the early stages of these illnesses, how ever, the flow changes may be more likely to be related to neurochemical dysfunction. In early Alz heimer's disease, where flow changes can be ob served, biopsy samples may show relatively few histopathological changes compared to functional ACh deficits (Bowen et aI., 1982; Prohovnik et aI., 1988; Rossor et aI. , 1982; Sims et aI., 1980) .
Our results indicate that characteristic rCBF and cognitive changes occur after scopolamine, but that these findings do not accurately model Alzheimer's disease. The approach taken, of pharmacologically dissecting CBF and cognitive mechanisms using drugs with specific actions does provide a key to mechanistic understanding of the dementias, and could be easily applied to other agents, for ex ample, clonidine which has been shown to exert cognitive effects (Arnsten and Goldman-Rakic, 1985; Frith et aI. , 1985) . Studies of reversal of sco polamine effects by physostigmine and neostigmine are ongoing in this laboratory.
Clinically, the frontal lobe deficits when ob served in Alzheimer's disease are noted to corre late with attentional and behavioral problems, also prominent features of Pick's disease (Chase et aI., 1984; Wechsler et aI., 1982) . Our results suggest that assessment of patient response to cholinergic and other forms of replacement therapy should in clude measures of frontal lobe function such as at tention and behavior. Early dementias with rela tively prominent impairments in these areas may be the most responsive to such treatments.
